Buprenorphine and Sodium Phosphate, Monobasic: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Sodium Phosphate, Monobasic
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Both buprenorphine (a pain and addiction medicine) and sodium phosphate can each nudge the heart's electrical rhythm in the same direction. This is called QT prolongation, and when two medicines push the same way, the effect can add up. In plain terms, it can make your heartbeat slightly more irregular in rare cases.
I want to be honest with you: this concern is theoretical, meaning it's based on how these drugs work rather than lots of real-world reports. The risk is mostly a worry if you have other heart concerns or low potassium or magnesium. Please don't stop either medicine on your own. Just check with your pharmacist or doctor so they can keep an eye on things.
Mechanism: additive QT-interval prolongation. Both agents are reported to have QT-prolonging potential; neither is a prodrug, so this is a pharmacodynamic (not metabolic) additive effect.
- Direction: increased combined risk of QTc prolongation and, theoretically, torsades de pointes.
- Evidence: theoretical; magnitude with this specific combination is not established.
- Onset: unspecified.
- Higher-risk patients: hypokalemia, hypomagnesemia, bradycardia, CHF, digitalis therapy, recent AF conversion, baseline or congenital QT prolongation.
- Management: avoid concomitant use where feasible; otherwise correct electrolytes and consider ECG monitoring. Individualize.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous administration of buprenorphine alongside agents capable of prolonging the QT interval should be avoided342. It remains unknown what risk arises when buprenorphine is paired with other QT-prolonging drugs. When prescribing buprenorphine to patients presenting risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, clinicians should take these observations into account in their decisions1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
What your care team may do:
- Weigh whether both drugs are truly needed at the same time, since the label advises avoiding this combination when possible.
- Check and correct low potassium or magnesium, which raise QT risk.
- Monitor you more closely (for example, an ECG) if you have heart risk factors.
What you should do: Keep taking both exactly as prescribed unless told otherwise. Tell your pharmacist or prescriber about any heart rhythm problems, fainting, dizziness, or a history of long QT. They can adjust and individualize your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Sodium Phosphate, Monobasic together?
Buprenorphine and sodium phosphate can each affect heart rhythm (QT), and using them together may add up, though this is a theoretical concern. Don't change anything on your own; ask your pharmacist or doctor, especially if you have heart issues or low potassium or magnesium. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Sodium Phosphate, Monobasic interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Sodium Phosphate, Monobasic interaction managed?
What your care team may do: Weigh whether both drugs are truly needed at the same time, since the label advises avoiding this combination when possible. Check and correct low potassium or magnesium, which raise QT risk. Monitor you more closely (for example, an ECG) if you have heart risk factors. What you should do: Keep taking both exactly as prescribed unless told otherwise. Tell your pharmacis… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Sodium Phosphate, Monobasic need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Sodium Phosphate, Monobasic
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist